Suzetrigine (Nav1.8 Non-Opioid Acute Pain)
Evidence grade scale used in this note:
- Confirmed — replicated clinical signals or well-supported mechanism statements
- Supported — single-study or preliminary evidence; directionally consistent
- Reported — observed in trials but not independently confirmed
- Contested — evidence is mixed or interpretation is debated
- Gap — not established in available literature
TL;DR
First-in-class selective Nav1.8 voltage-gated sodium channel inhibitor; FDA approved January 30, 2025 (brand: Journavx) for moderate-to-severe acute pain in adults. Statistically significant pain reduction vs placebo in two Phase 3 RCTs (abdominoplasty n=1,118; bunionectomy n=1,073); comparable efficacy to hydrocodone/acetaminophen (non-inferiority suggested; superiority NOT confirmed). No addiction risk, no respiratory depression, no GI ulceration. No long-term safety data; ~15 months on market as of April 2026.
Why it matters for Vitals
Vitals relevance:
- First evidence-backed non-opioid option for moderate-to-severe acute pain — directly relevant for pain protocol selection in users avoiding opioids
- Theoretical HRV/autonomic preservation signal vs opioid-based analgesia (not validated in trials — requires clinical review before Vitals coaching use)
- Non-NSAID mechanism for users with GI bleed history, renal impairment, or anticoagulation
- Oral, no device or cold-chain burden — straightforward for outpatient protocol integration
Wearables — evidence boundary: No wearable endpoints were measured in any suzetrigine trial. All HRV/sleep/activity monitoring claims are mechanistic extrapolation. human_signoff_required before any Vitals coaching use.
Key facts
| Field | Detail |
|---|---|
| Brand name | Journavx |
| Company | Vertex Pharmaceuticals |
| Class | Selective Nav1.8 voltage-gated sodium channel blocker |
| FDA approval | January 30, 2025 |
| Indication | Moderate-to-severe acute pain in adults |
| Dosing | 100 mg loading dose, then 50 mg every 12 hours (oral tablet) |
| First-in-class | First novel non-opioid acute pain mechanism approved in decades |
| Clinical trials | 2× Phase 3 RCTs (n=1,118; n=1,073) + single-arm Phase 3 (n=256) |
| Evidence boundary | ~15 months on market; no long-term or real-world data |
Mechanism summary
Suzetrigine selectively inhibits the Nav1.8 voltage-gated sodium channel, expressed almost exclusively in peripheral nociceptive neurons (C-fibers and A-delta fibers). Nav1.8 mediates the upstroke of the action potential in pain-sensing neurons and is critical for high-frequency repetitive firing during sustained pain signaling.
Confirmed:
- State-dependent (use-dependent) binding — preferentially targets channels in the inactivated state
- Activity-dependent mechanism: suppresses hyperactive nociceptors while sparing normally functioning neurons
- High selectivity for Nav1.8 over Nav1.5 (cardiac), Nav1.7, and Nav1.9 confirmed preclinically
- No CNS reward pathway activity (non-opioid mechanism)
- No COX inhibition (non-NSAID mechanism)
Distinct from: opioids (mu-receptor agonism), NSAIDs (COX inhibition), non-selective sodium channel blockers (lidocaine).
Evidence gaps: High-resolution cryo-EM structure of the suzetrigine–Nav1.8 complex not publicly disclosed. Selectivity ratios (Nav1.8 IC50 vs Nav1.5 IC50) not fully disclosed in indexed literature. Whether Nav1.8 inhibition differentially affects inflammatory vs neuropathic pain not established in human data.
Clinical efficacy
Phase 3 RCTs — Confirmed
Abdominoplasty RCT (n=1,118):
- SPID48 (primary): LS mean difference vs placebo = 48.4 (95% CI: 33.6–63.1), P < 0.0001
- Source: PMID 40117446
Bunionectomy RCT (n=1,073):
- SPID48 (primary): LS mean difference vs placebo = 29.3 (95% CI: 14.0–44.6), P = 0.0002
- Source: PMID 40117446
Phase 3 — secondary endpoint vs hydrocodone/acetaminophen — Confirmed (non-superiority)
- Suzetrigine did NOT achieve superiority vs hydrocodone/acetaminophen 5/325 mg q6h on SPID48 (pre-specified key secondary endpoint)
- Pain reduction was numerically comparable between treatments
- Time to ≥2-point NPRS reduction was faster with suzetrigine
- Source: PMID 40117446
Supporting evidence — Supported
- Meta-analysis (n=1,584): pain reduction at 24h MD −0.93 NPRS (95% CI: −1.38 to −0.48) vs placebo; pain reduction at 48h also statistically significant
- Heterogeneity note: I² = 66% — suggests variable efficacy across surgical models
- Single-arm Phase 3 (n=256): 83.2% rated effectiveness as good/very good/excellent; most adverse events mild (27.7%) or moderate (8.2%); no new safety signals
- Sources: PMID 41790692, PMID 40165940
Evidence gaps — Contested / Gap
- Clinically modest effect: ~1-point NPRS improvement over placebo at 24h; FDA approval narrative (“first non-opioid in decades”) may create expectations of a transformative advance — actual data shows comparable efficacy to opioids, not superior efficacy
- No head-to-head data vs ibuprofen, acetaminophen, or celecoxib
- Only two surgical models (abdominoplasty, bunionectomy); generalizability to other acute pain causes (renal colic, fracture, burns) is unestablished
- No efficacy data in chronic pain (Phase 2/3 for diabetic peripheral neuropathy and lumbosacral radiculopathy are ongoing)
- Population was 92.3% female — demographic generalizability unknown
- Long-term efficacy beyond 14 days not established
Pharmacokinetics — Supported
- Oral bioavailability confirmed; exact fraction not publicly disclosed in indexed literature (refer to FDA label)
- Dose-proportional PK across studied dose range (Phase 1 SAD study; PMID 41251403)
- Steady state reached in ~48 hours with twice-daily dosing (Phase 1 MAD; PMID 41251403)
- Primary metabolic pathway: CYP3A4 (PMID 41251403)
- No clinically significant CYP3A4 interactions at therapeutic concentrations in Phase 1 DDI assessments (PMID 41251403)
Gap: Exact half-life, protein binding %, food effect, Cmax/Tmax/clearance/Vd — not publicly disclosed in indexed literature. No dedicated renal/hepatic impairment PK study published. Active metabolites have not been clearly described.
Safety profile
Confirmed safety advantages vs opioids and NSAIDs
| Safety concern | Suzetrigine | Opioids | NSAIDs |
|---|---|---|---|
| Addiction risk | None (non-opioid) | High | None |
| Respiratory depression | None | Dose-dependent | None |
| GI ulceration | None | Constipation | Risk present |
| Cardiac (Nav1.5 cross-reactivity) | None detected | N/A | CV risk with COXibs |
Confirmed safety findings
- Adverse events were mild-to-moderate in severity in both Phase 3 RCTs; no new safety signals identified up to 14 days
- No abuse potential identified in abuse liability studies (PMID 41481839)
- No clinically significant Nav1.5 (cardiac) cross-reactivity confirmed preclinically and in Phase 3 cardiac monitoring (PMID 41924085)
Adverse events in trials — Supported
- Mild AEs: 27.7% (71/256); moderate AEs: 8.2% (21/256) in single-arm Phase 3
- Most common: dizziness, nausea, headache
- Source: PMID 40165940
Contraindications and warnings — Reported
- Known hypersensitivity to suzetrigine or any excipients
- Concomitant use with strong CYP3A4 inhibitors may require dose adjustment or be contraindicated
- Use in pregnancy only if benefit justifies risk (confirm current pregnancy category with FDA label)
- Use with caution in severe renal or hepatic impairment (not studied)
- Long-term (>14 days) safety not established in clinical trials
Special populations — Gap (not studied)
- Elderly patients >75 years (limited enrollment in Phase 3)
- Pediatric patients
- Pregnancy and lactation
- Severe renal or hepatic impairment
Post-marketing surveillance — Gap
As of April 2026, suzetrigine has been FDA-approved for approximately 15 months. No post-marketing pharmacovigilance data is publicly available in indexed literature.
Comparative landscape
| Comparison | Key distinction |
|---|---|
| vs opioids | Comparable efficacy; suzetrigine has no addiction risk, no respiratory depression, no constipation — NOT a replacement for opioids in severe acute pain requiring opioid-level analgesia; non-inferiority suggested, superiority NOT confirmed |
| vs NSAIDs | No GI/renal/CV toxicity; no head-to-head data; NSAIDs are cheaper and well-characterized for mild-moderate pain; comparative value of branded suzetrigine vs OTC NSAIDs for mild-moderate pain is not established |
| vs acetaminophen | Likely more efficacious for moderate-to-severe pain; acetaminophen remains safer in liver disease and first-line for mild pain; no head-to-head data |
| vs lidocaine | Oral vs IV; Nav1.8 selectivity avoids CNS toxicity and arrhythmia risk of non-selective sodium channel blockade |
| vs gabapentinoids | Fundamentally different mechanisms and indications; suzetrigine for acute pain; gabapentin/pregabalin for neuropathic/chronic pain |
Competitive position — Supported
Suzetrigine fills a specific niche as the first approved non-opioid, non-NSAID, non-acetaminophen option for moderate-to-severe acute pain. Value proposition is highest for:
- Patients with NSAID contraindications (GI bleed history, renal impairment, on anticoagulation)
- Patients at risk of or in recovery from opioid use disorder
- Multimodal ERAS protocols aiming to reduce opioid requirements
- Settings where addiction risk makes opioid prescribing undesirable
Not positioned as: replacement for OTC analgesics for mild pain.
Formulation and delivery — Confirmed
- Oral tablet formulation (small molecule, not a biologic or peptide)
- Dosing: 100 mg loading dose orally, then 50 mg every 12 hours
- No device burden: no injection, IV infusion, pump, or cold chain required
- No immunogenicity risk (small molecule)
- Simple oral administration — no healthcare professional required for administration; suitable for outpatient and discharge prescribing
Limitations:
- Twice-daily dosing may reduce compliance vs once-daily analgesics
- Patients unable to take oral medications (post-surgical NPO, severe nausea) cannot use it
- Not suitable for patients requiring rapid-onset IV analgesia in hospital settings
Gap: Specific inactive ingredients, available tablet strengths, scoring for dose adjustment, storage conditions, and bioequivalence data for potential generic formulations — not in indexed literature.
Vitals implementation guidance
⚠️
human_signoff_required— All Vitals coaching claims involving suzetrigine require clinical advisor review before user-facing use.
When to flag suzetrigine as an option (pending clinical review)
- User reports moderate-to-severe acute pain (post-procedure, injury) with NPRS ≥4
- NSAID contraindications present: GI bleed history, renal impairment, on anticoagulation, NSAID intolerance
- Opioid use disorder history or risk factors for opioid dependence
- ERAS/opioid-sparing multimodal protocol active
Not appropriate for Vitals coaching
- Mild acute pain (acetaminophen/ibuprofen remains first-line)
- Chronic pain (not approved; trials ongoing)
- Use in elderly >75, pediatric, pregnancy, severe organ impairment (not studied)
- Any specific HRV/wearable-based claims (no trial validation)
Theoretical wearable signal differentiation (speculative — requires clinical sign-off)
All of the following are mechanistic extrapolation. No wearable endpoints were measured in any suzetrigine trial.
| Theoretical signal | Mechanism basis | Evidence grade |
|---|---|---|
| HRV preservation vs opioid protocol | Opioids suppress HRV; suzetrigine is non-opioid and theoretically preserves autonomic function | Low — not measured in trials |
| Respiratory preservation | Opioids cause dose-dependent respiratory depression; suzetrigine causes none | Moderate — mechanistically supported, not directly measured |
| Sleep architecture preservation | Opioids disrupt deep sleep and REM; reducing opioids with suzetrigine may preserve sleep | Low — no direct sleep endpoint data |
| Pain recovery trajectory | Pain improvement correlates with HRV recovery and RHR normalization post-surgery | Low — associative only, not validated for suzetrigine |
Algorithm hooks
trigger_conditions:
suzetrigine_candidate:
when: "acute_pain_flag (NPRS 4+) AND (nsaid_contraindication OR opioid_risk OR opioid_sparing_goal)"
confidence: "conditional"
requires_clinical_review: true
evidence_boundary: "No validated wearable endpoint exists for suzetrigine efficacy"
opioid_sparing_coaching:
when: "suzetrigine_prescribed AND opioid_reduction_goal"
theoretical_signals: ["hrv_preserved", "resting_heart_rate_normal", "sleep_architecture_intact"]
evidence_boundary: "No trial data validating HRV/pain correlation for suzetrigine — theoretical only"
human_signoff_required: true
autonomic_recovery_benchmark:
when: "post_surgical AND analgesic_protocol"
comparison: "suzetrigine_protocol vs opioid_protocol"
theoretical_signals: ["hrv_trajectory", "rmssd_recovery", "step_count_progression"]
evidence_boundary: "No published comparative wearable data — associative only"
human_signoff_required: true
contraindications_absolute:
- "known_hypersensitivity_suzetrigine"
- "concomitant_strong_cyp3a4_inhibitor"
contraindications_relative:
- "pregnancy_benefit_risk_unclear"
- "severe_renal_impairment_not_studied"
- "severe_hepatic_impairment_not_studied"
- "elderly_over_75_limited_data"
- "pediatric_not_studied"
evidence_boundaries:
no_wearable_biomarker_validated: true
no_head_to_head_nsaid_data: true
no_long_term_safety_beyond_14_days: true
no_real_world_effectiveness_data: true
no_chronic_pain_efficacy: true
no_pediatric_pregnancy_data: true
human_signoff_required:
- "all_suzetrigine_coaching_recommendations"
- "all_wearable_based_recovery_benchmarking"
- "all_opioid_sparing_quantification_claims"Regulatory and access gaps
- EMA/MHRA status: Unknown — not confirmed in indexed literature as of April 2026
- Cost: Branded medication; high list price expected; insurance coverage varies; patient assistance programs may be available from Vertex
- Generics: Not expected for several years
Evidence summary
| Domain | Grade | Key Source |
|---|---|---|
| FDA approval | Confirmed | PMID 41771767 |
| Phase 3 efficacy (SPID48) | Confirmed | PMID 40117446 |
| Non-superiority vs opioids | Confirmed | PMID 40117446 |
| Mechanism (Nav1.8 selectivity) | Confirmed | PMID 39775738, PMID 41977224 |
| No abuse potential | Confirmed | PMID 41481839 |
| No respiratory depression | Confirmed | PMID 40117446 |
| No GI ulcer risk | Confirmed | PMID 40117446 |
| Mild/moderate AE profile | Supported | PMID 40165940 |
| CYP3A4 metabolism | Supported | PMID 41251403 |
| Oral bioavailability | Supported | PMID 41251403 |
| Meta-analysis efficacy (heterogeneity noted) | Supported | PMID 41790692 |
| Opioid-sparing role | Supported | PMID 41481839 |
| No Nav1.5 cross-reactivity | Supported | PMID 41924085 |
| Single-arm effectiveness (83% good+) | Supported | PMID 40165940 |
| HRV/autonomic preservation (wearable) | Gap (speculative) | Not measured in trials |
| Chronic pain efficacy | Gap | Phase 2/3 ongoing |
| Long-term (>14d) safety | Gap | Not studied |
| Real-world effectiveness | Gap | Post-marketing data not yet available |
| Head-to-head vs NSAIDs | Gap | No trials planned |
| Pediatric/pregnancy/elderly safety | Gap | Not studied |
Related notes
- Nav1.8 — voltage-gated sodium channel; primary mechanism target; no separate mechanism note yet (ghost link — create when a second compound targets this channel)
- Cluster Headache — pain condition note; suzetrigine not studied in this indication
- Body Systems MOC — pain management context
Key references
- PMID 40117446 — Phase 3 RCTs (abdominoplasty + bunionectomy), primary efficacy evidence
- PMID 40165940 — Phase 3 single-arm study, broad acute pain
- PMID 41790692 — Meta-analysis of efficacy (I² = 66%)
- PMID 41785614 — Safety meta-analysis
- PMID 39775738 — Nav1.8 selectivity mechanism
- PMID 41977224 — Nav1.8 peripheral expression
- PMID 41924085 — Nav1.8 electrophysiology and selectivity vs Nav1.5
- PMID 41800743 — Activity-dependent DRG neuron effects
- PMID 41481839 — Abuse liability and opioid-sparing rationale
- PMID 41251403 — Phase 1 PK/ADME
- PMID 41182481 — Comparative landscape vs gabapentinoids
- PMID 41771767 — FDA approval announcement
- PMID 41779973 — Health economic/access analysis